The δ-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats

Neuropsychopharmacology

Volumn 29, Issue 4, 2004, Pages 649-659

  Torregrossa, Mary M ^a   Isgor, Ceylan ^b   Folk, John E ^c   Rice, Kenner C ^c   Watson, Stanley J ^a,b   Woods, James H ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

opioid receptor; (+)BW373U86; Antidepressant; BDNF; in situ hybridization; TrkB

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BUSPIRONE; DELTA OPIATE RECEPTOR AGONIST; DESIPRAMINE; MESSENGER RNA; MIDAZOLAM;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT LIKE EFFECT; ARTICLE; BRAIN NUCLEUS; BRAIN PROTECTION; CONTROLLED STUDY; CONVULSION; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; ENDOPIRIFORM NUCLEUS; FRONTAL CORTEX; GENE EXPRESSION REGULATION; HIPPOCAMPUS; IN SITU HYBRIDIZATION; MALE; NONHUMAN; OLFACTORY CORTEX; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZAMIDES; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; BUPROPION; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG TOLERANCE; GENE EXPRESSION REGULATION; IMMOBILIZATION; IN SITU HYBRIDIZATION; MALE; MIDAZOLAM; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TRKB; RECEPTORS, OPIOID, DELTA; RNA, MESSENGER; SWIMMING; TIME FACTORS; UP-REGULATION;

EID: 1642447713     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300345     Document Type: Article

References (38)

1. Bishop MJ, McNutt RW (1995). An efficient synthesis of the benzhydrylpiperazine delta opioid agonist (+)BW373U86. Bioorg Med Chem Lett 5: 1311-1314.
2. Bofetiado DM, Mayfield KP, D'Alecy LG (1996). Alkaloid delta agonist BW373U86 increases hypoxic tolerance. Anesth Analg 82: 1237-1241.
3. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002a). Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 26: 744-755.
4. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002b). Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant effects in Sprague-Dawley rats. Psychopharmacology 164: 42-48.
5. Cahill CM, McClellan KA, Morinville A, Hoffert C, Hubatsch D, O'Donnell D et al (2001). Immunohistochemical distribution of delta opioid receptors in the rat central nervous system: evidence for somatodendritic labeling and antigen-specific cellular compartmentalization. J Comp Neurol 440: 65-84.
6. Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang K-J, DeCosta BR et al (1993). Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 215: 127-134.
7. Coppell AL, Pei Q, Zetterstrom TSC (2003). Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44: 903-910.
8. Duman RS (2002). Synaptic plasticity and mood disorders. Mol Psychiatry 7: S29-S34.
9. Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597-606.
10. Duman RS, Malberg J, Nakagawa S, D'Sa C (2000). Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48: 732-739.
11. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HWD, Simonin F et al (2000). Mice deficient for delta and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200.
12. George MS, Nahas Z, Li X, Kozel FA, Anderson B, Yamanaka K et al (2002). Novel treatments of mood disorders based on brain circuitry (ECT, MST, TMS, VNS, DBS). Semin Clin Neuropsychiatry 7: 293-304.
13. Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM (2001). Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Exp Neurol 172: 189-198.
14. Hong EJ, Rice KC, Calderon S, Woods JH, Traynor JR (1998). Convulsive behavior of nonpeptide delta opioid ligands: comparison of SNC80 and BW373U86 in mice. Analgesia 3: 269-276.
15. Isackson PJ, Huntsman MM, Murray KD, Gall CM (1991). BDNF mRNA expression is increased in adult rat forebrain after limbic seizures: temporal patterns of induction distinct from NGF. Neuron 6: 937-948.
16. Katoh-Semba R, Takeuchi IK, Inaguma Y, Ichisaka S, Hata Y, Tsumoto T et al (2001). Induction of brain-derived neurotrophic factor by convulsant drugs in the rat brain: involvement of region-specific voltage-dependent calcium channels. J Neurochem 77: 71-83.
17. Kraus RP, Chandarana P (1997). Say, are you psychiatrists still using ECT? Can Med Assoc J 157: 1375-1377.
18. Loscher W, Ebert U (1996). The role of the piriform cortex in kindling. Prog Neurobiol 50: 427-481.
19. Mackowiak M, O'Neill MJ, Hicks CA, Bleakman D, Skolnick P (2002). An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 43: 1-10.
20. Mansour A, Thompson RC, Akil H, Watson SJ (1993). Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J Chem Neuroanatomy 6: 351-362.
21. Mayfield KP, D'Alecy LG (1994). Delta-1 opioid agonist acutely increases hypoxic tolerance. J Pharmacol Exp Ther 268: 683-688.
22. McAllister AK, Katz LC, Lo DC (1999). Neurotrophins and synaptic plasticity. Annu Rev Neurosci 22: 295-318.
23. Meredith GE, Callen S, Scheuer DA (2002). Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex, and hypothalamus following repeated amphetamine administration. Brain Res 949: 218-227.
24. Middlemas DS, Lindberg RA, Hunter T (1991). TrkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol 11: 143-153.
25. Nibuya M, Morinobu S, Duman RS (1995). Regulation of BDNF and TrkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539-7547.
26. Pinna A, Di Chiara G (1998). Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC80: 3. Facilitation of D1 and D2 responses in unilaterally 6-hydroxydopamine-lesioned rats. Behav Pharmacol 9: 15-21.
27. Rage F, Givalois L, Marmigere F, Tapia-Arancibia L, Arancibia S (2002). Immobilization stress rapidly modulates BDNF mRNA expression in the hypothalamus of adult male rats. Neuroscience 112: 309-318.
28. Remick RA (2002). Diagnosis and management of depression in primary care: a clinical update and review. Can Med Assoc J 167: 1253-1260.
29. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al (2003). Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 23: 349-357.
30. Shirayama Y, Chen AC-H, Nakagawa S, Russell DS, Duman RS (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22: 3251-3261.
31. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997). Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56: 131-137.
32. Solum DT, Handa RJ (2002). Estrogen regulates the development of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus. J Neurosci 22: 2650-2659.
33. Spina L, Longoni R, Mulas A, Chang K-J, DiChiara G (1998). Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC80: 1. Locomotion, rearing and stereotypies in intact rats. Behav Pharmacol 9: 1-8.
34. Tejedor-Real P, Mico JA, Smadja C, Maldonado R, Roques BP, Gibert-Rahola J (1998). Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 354: 1-7.
35. Tsao L-I, Su T-P (2001). Hibernation-induction peptide and cell death: [D-Ala, D-Leu]enkephalin blocks Bax-related apoptotic processes. Eur J Pharmacol 428: 149-151.
36. Vaidya VA, Duman RS (2001). Depression - emerging insights from neurobiology. Br Med Bull 57: 61-79.
37. Wang ZH, Ji Y, Shan W, Zeng B, Raksadawan N, Pastores GM et al (2002). Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's Disease. Neuroscience 113: 629-640.
38. Yuan J, Yankner BA (2000). Apoptosis in the nervous system. Nature 407: 802-809.